ARE

Alexandria Real Estate remains a hold, with cautious optimism despite a 27% share price rebound and a near 7% yield. Q2 saw improved leasing activity exceeding 1 million square feet, but occupancy and same-store NOI continued to decline. Leverage increased to 7.0x, above peer levels, though management targets 5.6x–6.2x by year-end and maintains strong liquidity.

Investors need to pay close attention to ARE stock based on the movements in the options market lately.

Alexandria Real Estate Equities (ARE) remains a Buy, supported by a compelling margin of safety despite headwinds. ARE faces persistent supply-demand imbalances in key life science markets, but recent improvements in venture funding and leasing trends offer cautious optimism. Alexandria is responding defensively — asset sales, a 45% dividend cut, lower G&A, and a pivot to JV capital — as credit downgrades reflect the same headwinds already priced in.

Alexandria Real Estate has declined 75% in five years due to oversupply, higher rates, and a biotech funding slowdown. Despite recent negative rental rate changes and falling occupancy, ARE's best-in-class assets are positioned for a flight to quality as supply dries up. Life sciences market fundamentals are stabilizing, with construction pipelines shrinking and key markets showing early signs of recovery.

The Aug. 31 transaction was valued at $509,300. The sale involved shares equal to 9% of the stake held directly by the insider prior to the transaction.

PASADENA, Calif., Sept. 4, 2026 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, longest-tenured and pioneering owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced technology innovation clusters, today recognizes Blood Cancer Awareness Month by highlighting its strategic investments and tenants developing life-saving therapies in hematology and oncology, as well as the company's longstanding mission-critical engagement with the nation's leading nonprofits focused on blood cancers.

Alexandria Real Estate Equities, Inc. (ARE) is deeply undervalued, but technical entry timing is critical for optimal returns. ARE's FFO faces near-term headwinds from major lease expirations in 2027, with recovery expected as new leases and projects ramp up. I target a $45 average entry, buying in tranches on further weakness or a breakout above $55, to balance value and momentum.

PASADENA, Calif., Sept. 1, 2026 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE) today announced that its Board of Directors declared a quarterly cash dividend of $0.72 per common share for the third quarter of 2026.

PASADENA, Calif., Aug. 25, 2026 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE) today announced that the company will conduct a conference call and audio webcast on Tuesday, October 27, 2026, at 2:00 p.m.

Alexandria Real Estate Equities is mispriced as a distressed office REIT, offering a 'Strong Buy' opportunity. ARE's specialized life sciences campuses in top biotech hubs anchor high-quality tenants and provide a unique competitive moat. At a 50% discount to intrinsic value, ARE offers a 5.9% secure dividend yield and a robust balance sheet with $3.6 billion in liquidity.